ESPR
Esperion Therapeutics, Inc.
Set alert
- YTD
- -14.05%
- 1 year
- +211.76%
- Open
- 3.18
- Prev close
- 3.18
- Mkt cap
- 441.36M
- Vol
- 0
- Avg vol
- 5.64M
- EPS
- -0.67
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.18
- High
- 3.18
- Forward P/E
- 11.20
- Beta
- 0.95
- Short ratio
- 5.70
- Inst. own
- 66.34%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.41
- 200-d avg
- 2.24
- 1y target
- 7.51
Key statistics
- Market cap
- 441.36M
- Enterprise value
- 555.75M
- Trailing P/E
- 0.00
- Forward P/E
- 11.20
- PEG ratio
- 0.00
- Price / sales
- 1.49
- Price / book
- 0.00
- EPS (TTM)
- -0.67
- Beta
- 0.95
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -29.37%
- Revenue (TTM)
- 295.45M
- Revenue growth
- 52.00%
- Free cash flow
- -8.95M
- Total cash
- 144.72M
- Total debt
- 268.96M
- Return on equity
- 0.00%
- Shares outstanding
- 197.04M
- Short % of float
- 15.52%
- 50-day average
- 2.41
- 200-day average
- 2.24
Analyst view
Consensus: buy
- Target (low)
- 2.05
- Target (mean)
- 7.51
- Target (high)
- 16.00
- Strong buy3
- Buy2
- Hold1
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate -0.12529.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.14 | -0.15 | -0.01 | -7.14% |
| Aug 12, 2024 | Jun 1, 2024 | -0.15 | -0.05 | +0.10 | +66.67% |
| May 7, 2024 | Mar 1, 2024 | -0.08 | 0.34 | +0.42 | +525.00% |
| Feb 27, 2024 | Dec 1, 2023 | -0.53 | -0.50 | +0.03 | +5.66% |
| Nov 7, 2023 | Sep 1, 2023 | -0.42 | -0.37 | +0.05 | +11.90% |
| Aug 1, 2023 | Jun 1, 2023 | -0.63 | -0.46 | +0.17 | +26.98% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | Cantor Fitzgerald | init | — | Overweight |
| Dec 13, 2024 | Needham | reit | Buy | Buy |
| Dec 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 3, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- esperion.com
News
- Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
- Merck Just Won The Race For The First Cholesterol Pill: What It Means For Your Heart And Your Portfolio
- Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger
- 10 Health Care Stocks With Whale Alerts In Today’s Session
- Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
- Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- ESPR Stock Surges 44% in a Month: Here's What You Need to Know
- Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
- $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—PFLC, ESPR, LKSB, and MKC
Your note
Sign in to keep a note on ESPR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARROLL J MARTIN | Director | Stock Award(Grant) | May 22, 2024 | 64,650 |
| FISCHER SETH H Z | Director | Stock Award(Grant) | May 22, 2024 | 28,150 |
| FOODY JOANNE MICALE | Officer | Sale | Jul 16, 2024 | 272,862 |
| FUHRMAN ALAN CPA | Director | Stock Award(Grant) | May 22, 2024 | 53,404 |
| GOTTO ANTONIO M JR | Director | Stock Award(Grant) | May 22, 2024 | 51,599 |
| HALLADAY BENJAMIN | Chief Financial Officer | Sale | Dec 16, 2024 | 240,691 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wasatch Advisors LP | 11.85% | 23,346,013 | 52.30M | Sep 29, 2024 |
| Blackrock Inc. | 7.24% | 14,264,975 | 31.95M | Sep 29, 2024 |
| Vanguard Group Inc | 6.62% | 13,043,077 | 29.22M | Sep 29, 2024 |
| Bellevue Group AG | 5.05% | 9,944,064 | 22.27M | Sep 29, 2024 |
| Two Seas Capital Lp | 3.34% | 6,584,278 | 14.75M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.20% | 4,331,314 | 9.70M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wasatch Ultra Growth Fund | 3.39% | 6,675,165 | 14.95M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 3.14% | 6,179,587 | 13.84M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.47% | 4,866,712 | 10.90M | Oct 30, 2024 |
| Wasatch Small Cap Growth Fund | 2.23% | 4,397,143 | 9.85M | Sep 29, 2024 |
| Wasatch Microcap Fund | 2.14% | 4,211,030 | 9.43M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.31% | 2,575,610 | 5.77M | Sep 29, 2024 |